Asha Pharma

Executive Summary

Asha Pharma, a San Diego-based contract research organization (CRO) founded in 2018, specializes in solid form screening and selection to enhance the bioavailability of poorly soluble drugs. Its services—including polymorph, salt, and cocrystal screening, crystallization process development, and solid-state characterization—are critical in accelerating drug development from discovery to market. As a private, bootstrapped entity, Asha Pharma operates in a niche yet essential segment of the pharmaceutical value chain, serving clients seeking to optimize drug candidates' physical properties. The company's expertise in solid form science positions it well to benefit from the growing demand for solubility enhancement solutions, particularly as the industry focuses on difficult-to-formulate drug candidates. While the CRO market is competitive, Asha's specialized focus and San Diego location provide a foundation for steady growth, though its lack of disclosed funding or revenue implies a conservative scale. The company's success hinges on sustaining client relationships and adapting to evolving industry needs, such as biologics or novel modalities that also require solid form characterization.

Upcoming Catalysts (preview)

• TBDMajor contract win with top-20 pharma company30% success
• TBDLaunch of services for amorphous solid dispersions40% success